Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.
This report contains market size and forecasts of Lapatinib Ditosylate API in global, including the following market information:
Global Lapatinib Ditosylate API Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Lapatinib Ditosylate API Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Lapatinib Ditosylate API companies in 2021 (%)
The global Lapatinib Ditosylate API market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Min Purity Less Than 98% Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Lapatinib Ditosylate API include VulcanChem, FCDA, Tecoland, Kumidas, MuseChem, Huirui Pharma, Shengda Pharmaceutical, Shijiazhuang Dingmin Pharmaceutical Sciences and ScinoPharm Taiwan, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Lapatinib Ditosylate API manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Lapatinib Ditosylate API Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Lapatinib Ditosylate API Market Segment Percentages, by Type, 2021 (%)
Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%
Global Lapatinib Ditosylate API Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Lapatinib Ditosylate API Market Segment Percentages, by Application, 2021 (%)
Research
Pharmaceutical
Global Lapatinib Ditosylate API Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Lapatinib Ditosylate API Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Lapatinib Ditosylate API revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Lapatinib Ditosylate API revenues share in global market, 2021 (%)
Key companies Lapatinib Ditosylate API sales in global market, 2017-2022 (Estimated), (MT)
Key companies Lapatinib Ditosylate API sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
VulcanChem
FCDA
Tecoland
Kumidas
MuseChem
Huirui Pharma
Shengda Pharmaceutical
Shijiazhuang Dingmin Pharmaceutical Sciences
ScinoPharm Taiwan
Shenzhen InnoSyn Biotech
Shandong Boyuan Pharmaceutical